Cook Medical‘s Regentec division said today that it launched the ProFusion therapeutic infusion needle designed for the intramuscular or subdermal infusion of therapeutic agents in the U.S. and Canada.
The Indianapolis-based business said that the ProFusion Therapeutic Infusion Needle features multiple sideports arranged in a spiral to aid in the uniform delivery and dispersement of therapeutic agents and a trocar tip to help with placement.
“Cook Regentec is committed to innovating tools that better assist clinicians in delivering therapeutics precisely, accurately and consistently. We’re pleased to add the ProFusion Therapeutic Infusion Needle to our product line and provide another tool for physicians to improve patient care,” Cook Regentec biz leader Brad Shirley said in a press release.
Last month, the journal Circulation said that the all-cause mortality rates in a study comparing a paclitaxel stent from Cook Medical and percutaneous transluminal angioplasty in people with peripheral artery disease were “inadvertently reversed” by the authors.
